NICE recommends Adcetris (brentuximab vedotin) as a treatment for relapsed or refractory systemic anaplastic large cell lymphoma.-Takeda Oncology.

The National Institute for Health and Care Excellence (NICE) has issued new guidance supporting Adcetris (brentuximab vedotin) from Takeda Oncology as a treatment for relapsed or refractory systemic anaplastic large cell lymphoma, a rare form of non-Hodgkin’s lymphoma, subject to a confidential discount offered by Takeda Oncology. NICE’s final appraisal document (FAD) states: Brentuximab vedotin is recommended as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if: they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and the company provides brentuximab vedotin according to the commercial access agreement with NHS England.